BETH ISRAEL DEACONESS MEDICAL CENTER
Hemopexin as an Early Biomarker of Anthracycline Cardiac Toxicity
Hemopexin as an Early Biomarker of Anthracycline Cardiac Toxicity is a funding opportunity from BETH ISRAEL DEACONESS MEDICAL CENTER, up to 633596, closing March 31, 2027.
Mar 31, 2027
(243d left)Overview
PROJECT SUMMARY This project seeks to contribute new insights into the role of heme metabolism in the pathogenesis of anthracycline cardiac toxicity by leveraging studies in human patients and mouse models. The project will be led by Aarti Asnani, MD, Cardiologist and Director of Cardio-Oncology at Beth Israel…